Patients, Families & Physicians

"We are disruptive by design. From our breakthrough SINTAX platform and transformative SINTAX-based medicines, to our commitment to altering the traditional business model to enable broad access to medicines, we have the potential to deliver effective, safe, well-tolerated and affordable oral medicines to billions of people globally who suffer from inflammatory disease and who currently have limited treatment options. Disruption is at our core and embedded in our unwavering dedication to make possible what others might think is impossible or are simply too afraid to try."

“I see a lot of patients with psoriasis or atopic dermatitis in the dermatology clinic. While there are some very effective medicines available for patients with more severe disease, the vast majority of patients have mild and moderate disease and remain untreated, or have to use topical treatments, giving them very limited options. As a clinician, I want to be able to offer patients an oral, safe, well-tolerated therapy that can resolve the skin and systemic manifestations of disease. I want to be able to offer this early on in their treatment journey, without having to prescribe toxic or inconvenient therapies. This is why I joined Evelo – I saw that potential of EDP1815 and I am excited that we are building towards a treatment solution for so many patients with a range of inflammatory diseases.”